Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group - Takeaways - MDSpire

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

  • By

  • Lan-Ping Xu

  • Pei-Hua Lu

  • De-Pei Wu

  • Zi-Min Sun

  • Qi-Fa Liu

  • Ming-Zhe Han

  • Xi Zhang

  • Yong-Ping Song

  • Xian-Min Song

  • Jian-da Hu

  • He Huang

  • Yong-Rong Lai

  • Ding-Ming Wan

  • Jing Chen

  • Chun-Fu Li

  • Ling-Hui Xia

  • Jing-Bo Wang

  • Dai-Hong Liu

  • Xiao-Jun Huang

  • August 25, 2021

  • 0 min

Share

  • 1

    In 2019, China performed over 12,000 hematopoietic stem cell transplants (HSCT), marking the first time annual transplants exceeded 10,000.

  • 2

    Of the HSCTs in 2019, 78% were allogeneic, with haploidentical donors accounting for 60% of these procedures.

  • 3

    The median age of HSCT patients was 31 years, with 42% being female and 58% male; pediatric patients comprised 30% of the total.

  • 4

    The most common indications for HSCT were acute leukemia, with acute myeloid leukemia and acute lymphoblastic leukemia being the predominant types.

  • 5

    The transplant rates for allogeneic and autologous HSCT in China were 68.5 and 19.4 per 10 million population, respectively.

Original Source(s)

Related Content